Overview
UK-based psychedelic drug development company advancing novel ketamine and esketamine analogs for treatment-resistant depression and other psychiatric conditions. They focus on improving upon existing approved psychedelic medicines with next-generation compounds.
More in Psychedelics
Latest industry news
China Performs World's First Commercial BCI Implant, Marking a Pivotal Moment in the Global Brain-Computer Interface Race
2026-07-16 · Industry
NIH Confirms Brain-Computer Device Restores Speech in Human Patient
2026-07-15 · Research
Neurovalens Wins FDA Approval for Wearable PTSD Therapy Aimed at US Veterans
2026-07-14 · Policy
BRYM Raises €650K to Build Wearable Neurofeedback Platform for Consumer and Clinical Markets
2026-07-13 · Funding
Company details
Category
🍄 Psychedelics
Location
London, United Kingdom
Funding
Seed · $7M
Website
clerkenwelllabs.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →